30 January 2021: Clinical Research
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
Naibo Hu 12DE , Tiejun Qin 1B , Xiaoyan Du 3C , Bingyi Wang 3DE , Xiaoyun Wang 3E , Zefeng Xu 1DF , Lijuan Pan 1F , Shiqiang Qu 1DF , Zhijian Xiao 1A*DOI: 10.12659/MSM.928454
Med Sci Monit 2021; 27:e928454
Table 3 Treatment responses.
| Indicators | Total (n=158) | Azacitidine (n=38) | Decitabine (n=120) | P value |
|---|---|---|---|---|
| 2 [1–4] | 2 [1–4] | 2 [1–4] | 0.499 | |
| 1 [1–2] | 1 [1–2] | 1 [1–2] | 0.830 | |
| CR | 8 (5.1%) | 1 (2.6%) | 7 (5.8%) | 0.680 |
| mCR | 66 (41.8%) | 12 (31.6%) | 54 (45.0%) | 0.186 |
| PR | 0 | |||
| HI (without CR+mCR+PR) | 17 (10.8%) | 3 (7.9%) | 14 (11.7%) | 0.764 |
| Stable disease | 29 (18.4%) | 8 (21.1%) | 21 (17.5%) | 0.634 |
| Failure | 30 (19.0%) | 12 (31.6%) | 18 (15.0%) | 0.032* |
| Not assessed | 2 (1.3%) | 2 (5.3%) | 0 | 0.057 |
| ORR (CR+mCR+PR+HI) | 91 (57.6%) | 16 (42.1%) | 75 (62.5%) | 0.037* |
| HI-E | 43 (27.2%) | 5 (13.2%) | 38 (31.7%) | 0.035* |
| HI-N | 57 (36.1%) | 9 (23.7%) | 48 (40.0%) | 0.082 |
| HI-P | 40 (25.3%) | 8 (21.1%) | 32 (26.7%) | 0.529 |
| 62 (39.2%) | 12 (31.6%) | 50 (41.7%) | 0.341 | |
| 48 (30.4%) | 6 (15.8) | 42 (35.0%) | 0.026* | |
| Parametric continuous variables are presented as mean (SD); nonparametric variables are reported as median [IQR]; categorical variables are represented as a number (percentage within the category). * CR – complete remission; HI – hematologic improvement; HI-E – HI-erythroid; HI-N – HI-neutrophil; HI-P – HI-platelet; mCR – marrow complete response; PD – progressive disease; ORR – overall response rate; PLT – platelets; PR – partial response; RBC – red blood cells. | ||||